Long‐term outcomes of neoadjuvant gemcitabine, nab‐paclitaxel , and S1 ( GAS ) in borderline resectable pancreatic cancer with arterial contact: Results from a phase II trial
Journal of Hepato-Biliary-Pancreatic Sciences · 2024
DOI: 10.1002/jhbp.1412 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Hepato-Biliary-Pancreatic Sciences, 2024. Verfasst von Kenichiro Uemura und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Deoxycytidine, Gemcitabine, Paclitaxel. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
Background/Purpose This study reports the long‐term results of a phase II trial evaluating the clinical efficacy of neoadjuvant gemcitabine, nab‐paclitaxel, and S1 (GAS) in borderline resectable pancreatic cancer with arterial contact (BRPC‐A).
Methods
A multicenter, single‐arm, phase II trial was conducted. Patients received six cycles of GAS and patients without progressive disease were intended for R0 resection.
Results
Of the 47 patients, 45 (96%) underwent pancreatectomy. At the time of this analysis, all patients were updated with no loss to follow‐up. A total of 30 patients died, while the remaining 17 patients were followed for a median of 68.1 months. The updated median overall survival (OS) was 41.0 months, with 2‐ and 5‐year OS rates of 68.0% and 44.6%, respectively. Multivariate analysis in the preoperative model showed that a tumor diameter reduction rate ≥10% and a CA19‐9 reduction rate ≥95% after neoadjuvant chemotherapy remained independently associated with favorable survival. In the postoperative multivariate model, no lymph node metastasis, no major surgical complications, and completion of adjuvant chemotherapy were independently associated with improved OS.
Conclusions
This long‐term evaluation of the neoadjuvant GAS trial demonstrated the high efficacy of the regimen, suggesting that it is a promising treatment option for patients with BRPC‐A.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
- Department of Surgery, Kure Medical Center and Chugoku Cancer Center, Hiroshima, Japan.
- Department of Surgery, Hiroshima Memorial Hospital, Hiroshima, Japan.
ORCID-Profile: Kenichiro Uemura, Naru Kondo, Kenjiro Okada
Zitieren
APA
Uemura, K., Kondo, N., Sudo, T., Sumiyoshi, T., Shintakuya, R., Okada, K., Baba, K., Harada, T., Murakami, Y., & Takahashi, S. (2024). Long‐term outcomes of neoadjuvant gemcitabine, nab‐paclitaxel , and S1 ( GAS ) in borderline resectable pancreatic cancer with arterial contact: Results from a phase II trial. Journal of Hepato-Biliary-Pancreatic Sciences. https://doi.org/10.1002/jhbp.1412
Vancouver
Uemura K, Kondo N, Sudo T, Sumiyoshi T, Shintakuya R, Okada K, et al. Long‐term outcomes of neoadjuvant gemcitabine, nab‐paclitaxel , and S1 ( GAS ) in borderline resectable pancreatic cancer with arterial contact: Results from a phase II trial. Journal of Hepato-Biliary-Pancreatic Sciences. 2024. doi:10.1002/jhbp.1412
BibTeX
@article{Uemura2024,
author = {Uemura, Kenichiro and Kondo, Naru and Sudo, Takeshi and Sumiyoshi, Tatsuaki and Shintakuya, Ryuta and Okada, Kenjiro and Baba, Kenta and Harada, Takumi and Murakami, Yoshiaki and Takahashi, Shinya},
title = {Long‐term outcomes of neoadjuvant gemcitabine, nab‐paclitaxel , and S1 ( GAS ) in borderline resectable pancreatic cancer with arterial contact: Results from a phase II trial},
journal = {Journal of Hepato-Biliary-Pancreatic Sciences},
year = {2024},
doi = {10.1002/jhbp.1412}
}
EUVIMED